Prognostic implication of 1-year decline in diffusing capacity in newly diagnosed idiopathic pulmonary fibrosis
Authors:
Open Access
- 17 April 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Abstract
The progression of idiopathic pulmonary fibrosis (IPF) is assessed through serial monitoring of forced vital capacity (FVC). Currently, data regarding the clinical significance of longitudinal changes in diffusing capacity for carbon monoxide (DLCO) is lacking. We investigated the prognostic implications of a 1-year decline in DLCO in 319 patients newly diagnosed with IPF at a tertiary hospital between January 2010 and December 2020. Changes in FVC and DLCO over the first year after the initial diagnosis were reviewed; a decline in FVC ≥ 5% and DLCO ≥ 10% predicted were considered significant changes. During the first year after diagnosis, a significant decline in FVC and DLCO was observed in 101 (31.7%) and 64 (20.1%) patients, respectively. Multivariable analysis showed that a 1-year decline in FVC ≥ 5% predicted (aHR 2.74, 95% CI 1.88–4.00) and 1-year decline in DLCO ≥ 10% predicted (aHR 2.31, 95% CI 1.47–3.62) were independently associated with a higher risk of subsequent mortality. The prognostic impact of a decline in DLCO remained significant regardless of changes in FVC, presence of emphysema, or radiographic indications of pulmonary hypertension. Therefore, serial monitoring of DLCO should be recommended because it may offer additional prognostic information compared with monitoring of FVC alone.Keywords
This publication has 32 references indexed in Scilit:
- CT‐determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosisRespirology, 2017
- Idiopathic pulmonary fibrosisThe Lancet, 2017
- Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Examination of the Carbon Monoxide Diffusing Capacity (D l CO) in Relation to Its K co and V a ComponentsAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Test Properties and Minimal Clinically Important DifferenceAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Changes in Forced Expiratory Volume in 1 Second over Time in COPDNew England Journal of Medicine, 2011
- Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011